The enzyme cyclic GMP-AMP synthase stimulates the immune response during HIV infections
http://www.chemistryviews.org/details/news/5109171/Cyclic_Dinucleotide_Senses_HIV.html
The enzyme cyclic GMP-AMP synthase stimulates the immune response during HIV infections
http://www.chemistryviews.org/details/news/5109171/Cyclic_Dinucleotide_Senses_HIV.html
Transthyretin, or TTR for amyloidosis
THURSDAY Aug. 29, 2013 — A new medication appears to be highly effective in combating a heredity-based form of the organ-damaging genetic disorder known as amyloidosis, according to researchers.
Amyloidosis refers to a family of more than a dozen diseases in which different types of abnormal proteins called amyloids lodge in major organs and nerves. These amyloids build up to the point that they cause damage and, ultimately, organ failure.
read all at
http://www.drugs.com/news/experimental-shows-promise-rare-genetic-disorder-47059.html
Transthyretin (TTR) is a serum and cerebrospinal fluid carrier of the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol. This is how transthyretin gained its name, transports thyroxine and retinol. The liver secretes transthyretin into the blood, and the choroid plexus secretes TTR into thecerebrospinal fluid.
TTR was originally called prealbumin[1] (or thyroxine-binding prealbumin) because it ran faster than albumin on electrophoresis gels.
It functions in concert with two other thyroid hormone-binding proteins in the serum:
Protein | Binding strength | Plasma concentration |
---|---|---|
thyroxine-binding globulin (TBG) | highest | lowest |
transthyretin (TTR) | lower | higher |
albumin | poorest | much higher |
In cerebrospinal fluid TTR is the primary carrier of T4. TTR also acts as a carrier ofretinol (vitamin A) through its association with retinol-binding protein (RBP) in the blood and the CSF. Less than 1% of TTR’s T4 binding sites are occupied in blood, which is taken advantage of below to prevent TTRs dissociation, misfolding and aggregation which leads to the degeneration of post-mitotic tissue.
Numerous other small molecules are known to bind in the thyroxine binding sites, including many natural products (such as resveratrol), drugs (Tafamidis,[2] or Vyndaqel, diflunisal,[3][4][5] flufenamic acid),[6] and toxins (PCB[7]).
TTR is a 55kDa homotetramer with a dimer of dimers quaternary structure that is synthesized in the liver, choroid plexus and retinal pigment epithelium for secretion into the bloodstream, cerebrospinal fluid and the eye, respectively. Each monomer is a 127-residue polypeptide rich in beta sheet structure. Association of two monomers via their edge beta-strands forms an extended beta sandwich. Further association of two of these dimers in a face-to-face fashion produces the homotetrameric structure and creates the two thyroxine binding sites per tetramer. This dimer-dimer interface, comprising the two T4 binding sites, is the weaker dimer-dimer interface and is the one the comes apart first in the process of tetramer dissociation.[8]
The microfilament cytoskeleton protein actin plays an important role in cell biology and affects cytokinesis, morphogenesis, and cell migration. These functions usually fail and become abnormal in cancer cells. The marine-derived macrolides latrunculins A and B, from the Red Sea sponge Negombata magnifica, are known to reversibly bind actin monomers, forming 1:1 stoichiometric complexes with G-actin, disrupting its polymerization. To identify novel therapeutic agents for effective treatment of metastatic breast cancer, several semisynthetic derivatives of latrunculin A with diverse steric, electrostatic, and hydrogen bond donor and acceptor properties were rationally prepared. Analogues were designed to modulate the binding affinity toward G-actin. Examples of these reactions are esterification, acetylation, and N-alkylation. Semisynthetic latrunculins were then tested for their ability to inhibit pyrene-conjugated actin polymerization, and subsequently assayed for their antiproliferative and anti-invasive properties against MCF7 and MDA-MB-231 cells using MTT and invasion assays, respectively.
Mohammad A. Khanfar, Diaa T. A. Youssef and Khalid A. El Sayed
Article first published online: 30 DEC 2009 | DOI: 10.1002/cmdc.200900430
Volume 5, Issue 2, pages 274–285, February 1, 2010
Negombata magnifica, a Red Sea sponge (background), is the natural source of latrunculin A. A series of latrunculin A derivatives were synthesized and tested for their ability to inhibit G-actin polymerization and breast cancer cell proliferation and invasion. Molecular modeling simulations (inset) were applied to improve the understanding of the SAR of latrunculins.
Pioglitazone increases the body’s sensitivity to insulin
Suspension of cheap and popular medicine reversed but will now come with new safety warnings
http://www.rsc.org/chemistryworld/2013/08/india-u-turn-diabetes-pioglitazone-drug-ban
AUGUST 20, 2013
UK patients with a certain type of skin cancer can now get access to Roche’s once-daily pill Erivedge following its launch in the country.
Erivedge(vismodegib)胶囊
Erivedge (vismodegib) is the first medicine available in the UK for the treatment of patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC that is unsuitable for surgery or radiotherapy.
http://www.pharmatimes.com/Article/13-08-20/Roche_s_new_skin_cancer_drug_now_available_in_UK.aspx
ROCHESTER, Minn. — A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer
http://www.pharmalive.com/study-brain-cancer-survival-improved-following-fda-approval-of-avastin
STR REF –http://www.kidneycancerinstitute.com/Bevacizumab.html
IN CASE U NEED TO CONTACT ME THEN MAIL ME. amcrasto@gmail.com
Bevacizumab (trade name Avastin, Genentech/Roche) is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.
Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically availableangiogenesis inhibitor in the United States.
Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certainmetastatic cancers. It received its first approval in 2004, for combination use with standardchemotherapy for metastatic colon cancer.It has since been approved for use in certain lung cancers, renal cancers, and glioblastoma multiforme of the brain.
At one point bevacizumab was approved for breast cancer by the FDA, but the approval was revoked on 18 November 2011. The approval for breast cancer was revoked because, although there was evidence that it slowed progression of metastatic breast cancer, there was no evidence that it extended life or improved quality of life, and it caused adverse effects including severe high blood pressure and hemorrhaging. In 2008, the FDA gave bevacizumab provisional approval for metastatic breast cancer, subject to further studies. The FDA’s advisory panel had recommended against approval. In July 2010, after new studies failed to show a significant benefit, the FDA’s advisory panel recommended against the indication for advanced breast cancer. Genentech requested a hearing, which was granted in June 2011. The FDA ruled to withdraw the breast cancer indication in November 2011. FDA approval is required for Genentech to market a drug for that indication. Doctors may sometimes prescribe it for that indication, although insurance companies are less likely to pay for it. The drug remains approved for breast cancer use in other countries including Australia.
Clinical trials are underway for many other indications including ovarian cancer, pediatric osteosarcoma, and certain non-malignant eye diseases. In the curative setting (adjuvant therapy), clinical studies are underway in breast cancer and lung cancer.
MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ — Upsher-Smith Laboratories, Inc., today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo™ (testosterone) gel for topical use CIII
http://www.pharmalive.com/upsher-smith-gets-tentative-nda-approval-for-vogelxo-gel
Theravance Inc. said Wednesday it is antibiotic Vibativ is now back on the market. Vibativ was approved as a treatment for complex skin infections in 2010, and it was approved for use against hospital-acquired pneumonia in June 2013. It is Theravance’s only approved drug.
read all at
http://www.dddmag.com/news/2013/08/vibativ-back-market?et_cid=3425506&et_rid=523035093&type=cta
PARSIPPANY, N.J. and DUBLIN, IRELAND – August 9, 2013 – Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced that they have received approval from the French Competition Authority for Actavis’ pending acquisition of Warner Chilcott. The companies previously received approval from the German Federal Cartel Office and have now received all ex-U.S. antitrust clearances required to complete the transaction.
read all at
http://www.pharmalive.com/french-authorities-approve-actavis-acquisition-of-warner-chilcott
………………………
………..
Bethlehem